Compare Hilton Hotels Corporation Common Stock (HLT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs TG Therapeutics Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $322.53 (market cap $70.82B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 9.3× TG Therapeutics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HLT | TGTX | |
|---|---|---|
Market Cap | $70.82B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $59.06 |
52-Week Low | $256.75 | $26.94 |
Enterprise Value | $83.83B | $7.84B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.16, up 3.91% over 24 hours, with a bullish analyst consensus of 57% buy ratings and a $352 price target. Recent earnings have consistently beaten estimates, with Q2 2026 EPS at $2.29 matching expectations. The stock shows bearish technical signals but strong fundamentals, including revenue growth to $12.04B in 2025 and a net income margin of 12.69%. However, rising debt levels and a high P/E ratio of 46.21 pose valuation concerns.
The outlook for HLT is positive due to robust travel demand and a growing hotel pipeline, though premium valuation and increasing debt require caution. Investment opportunity lies in sustained earnings growth and capital returns, while risks include economic sensitivity and labor disputes, as highlighted by ongoing strikes and soft Q3 guidance affecting investor sentiment.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
